Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic human bone marrow mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Guangzhou Saijun Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic human bone marrow mesenchymal stem cells (hBM-MSCs) are multipotent stromal cells harvested from the bone marrow of healthy donors, expanded in vitro, and administered as a cell therapy. These cells possess significant immunomodulatory, anti-inflammatory, and regenerative properties, which are primarily mediated through the secretion of paracrine factors such as cytokines and growth factors. In the context of sarcopenia-osteoporosis syndrome, hBM-MSCs are intended to counteract age-related muscle wasting and bone loss by promoting the differentiation of resident progenitor cells into myocytes and osteoblasts while suppressing chronic systemic inflammation (inflammaging). Guangzhou First People's Hospital is currently evaluating these cells in a Phase 1 clinical trial involving repeated intravenous infusions in elderly patients to assess safety and preliminary efficacy in improving muscle mass, strength, and bone mineral density.
- Other names
- allogeneic bone marrow mesenchymal stem cellshBM-MSCsallogeneic human bone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic human bone marrow mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic human bone marrow mesenchymal stem cells.